Literature DB >> 8765437

Effects of lipophilicity and protein binding on the hepatocellular uptake and hepatic disposition of two anthracyclines, doxorubicin and iododoxorubicin.

L P Rivory1, K M Avent, S M Pond.   

Abstract

The anthracyclines, in particular doxorubicin (DOX), have been used for the intra-arterial locoregional therapy of liver tumours for over two decades. However, the results obtained with this form of therapy have been disappointing. It is widely recognised that DOX has a slow and limited tissue uptake, and we hypothesised that lipophilic analogues could be more suitable for locoregional administration. Using rat hepatocyte suspensions and the isolated rat liver, we examined the effects of lipophilicity, as determined from the octanol: buffer partition coefficient (Koct:buf), and protein binding of several anthracyclines on hepatocellular uptake. In particular, we compared DOX with 4'-iodo-4'-deoxy-doxorubicin (IDX), which differs only in the substitution of the daunosamine hydroxyl by an iodine molecule. Using a direct spectrofluorimetric method to evaluate cell uptake, we found that the influx rates correlated with the logarithm of Koct:buf and that IDX had the highest rate. However, the addition of bovine serum albumin (BSA) to the medium reduced the hepatocellular uptake of IDX more extensively than that of DOX such that the DOX uptake exceeded that of IDX with 4% BSA. Experiments in the isolated perfused rat liver confirmed these findings. We suggest that a trade-off of cellular uptake for reduced protein binding is desirable in the selection of drugs for intrahepatic administration. This may be accomplished by choosing anthracyclines with intermediate lipophilicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765437     DOI: 10.1007/s002800050508

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Recombinant Synthesis of Hybrid Lipid-Peptide Polymer Fusions that Self-Assemble and Encapsulate Hydrophobic Drugs.

Authors:  Kelli M Luginbuhl; Davoud Mozhdehi; Michael Dzuricky; Parisa Yousefpour; Fred C Huang; Nicholas R Mayne; Kristen L Buehne; Ashutosh Chilkoti
Journal:  Angew Chem Int Ed Engl       Date:  2017-10-09       Impact factor: 15.336

2.  Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

3.  Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1997-08

4.  Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Authors:  Amir Ashoorzadeh; Alexandra M Mowday; Christopher P Guise; Shevan Silva; Matthew R Bull; Maria R Abbattista; Janine N Copp; Elsie M Williams; David F Ackerley; Adam V Patterson; Jeff B Smaill
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-01

5.  A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors.

Authors:  Petko Alov; Merilin Al Sharif; Denitsa Aluani; Konstantin Chegaev; Jelena Dinic; Aleksandra Divac Rankov; Miguel X Fernandes; Fabio Fusi; Alfonso T García-Sosa; Risto Juvonen; Magdalena Kondeva-Burdina; José M Padrón; Ilza Pajeva; Tania Pencheva; Adrián Puerta; Hannu Raunio; Chiara Riganti; Ivanka Tsakovska; Virginia Tzankova; Yordan Yordanov; Simona Saponara
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.